Table 4.

Cysteines modified upon methyl viologen-mediated oxidation.

No.	Protein name	Peptide sequence	Predicted mass		Observed mass in MV treatment
			NEM	Biotin maleimide
1	RubisCO large subunit	AVYEC*LR	978.0	1304.5	1304.61*
2	Myrosinase	C*SPKIDVR	1113.5	1440.0	1439.69*
19	NAD(P)-binding Rossmann-fold-containing protein	SLVSDSTSICGPSKFTGK	1938.9	2265.4	1938.1
21	Ferredoxin-NADP(+) oxidoreductase 1 (FNR1)	C*LLNTK	815.9	1142.4	1142.57*

The table shows the peptide sequence and the predicted mass in the presence of the alkylating agents either NEM or biotin maleimide. The mass observed in MALDI-TOF MS of the MV-treated sample is shown. NEM-labeled cysteine (C) mass matches to experimental mass value suggesting that these Cys are not modified during oxidation. C* denotes Cys in the peptide sequence which is labeled with biotin maleimide, since the predicted mass matched to the experimentally observed value.The underlined peptides were addressed to be modified also in in vitro oxidation treatment (refer Table 2).